nitric oxide system raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-11-26. Anything still debated is marked as such rather than presented as settled.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
These cells are activated after injury and are required for fibroblast migration during the wound healing process. The Horsley laboratory discovered that aging causes the loss of dermal adipocyte precursor cells regeneration, and therefore requires Pdgf signaling. Furthermore, adipocytes stem cells can form myofibroblasts after skin injury that generate extracellular matrix proteins and crosslink collagen and these cells are stimulated by macrophage-derived signaling proteins. Her research provides a link between the communication of various cells which lead to hair growth and wound healing, revealing a framework for the possible regulation of tissue repair and the development of various diseases. Mechanical forces are known to regulate the development, homeostasis and regeneration of multicellular tissues. To illustrate the mechanics involved in skin function, Horsley with E. Dufresne, used traction force microscopy to discover the physical properties of epithelial cell clusters. Using genetics, function-blocking antibodies and mathematical modeling, their work revealed the significance of physical cohesion through cadherin molecules with the coordination of mechanical force throughout multicellular clusters. Together with M. King, they identified a role of nuclear-cytoskeletal adhesion during the growth of the hair follicle. They found that inner nuclear membrane proteins of the Sun family are required for the process of keratinocyte adhesion and hair follicle structure through regulation of the cytoskeleton.
Since bandwagoning "requires placing trust in the aggressors continued forbearance" some realists believe balancing is preferred to bandwagoning. According to Stephen Walt, states are more likely to balance in peacetime but if they are on the losing side of a war they may defect and bandwagon in the hopes that they will "share the fruits of victory".
The Peruvian government declares that an ENSO Costero is under way if the sea surface temperature deviation in the Niño 1+2 regions equal or exceed 0.4 °C (0.72 °F) for at least three months. The United Kingdom's Met Office also uses a several month period to determine ENSO state. When this warming or cooling occurs for only seven to nine months, it is classified as El Niño/La Niña "conditions"; when it occurs for more than that period, it is classified as El Niño/La Niña "episodes". The India Meteorological Department (IMD) incorporates ENSO monitoring into its operational forecasting framework, as ENSO is one of the principal drivers of interannual variability in the Indian summer monsoon. According to the IMD, ENSO conditions are assessed alongside the Indian Ocean Dipole (IOD) using surface and upper-air observations, satellite and radar data, ocean observations and numerical weather prediction models.
Sources: en.wikipedia.org
Astatine (85At) has 41 known isotopes, all of which are radioactive, whose mass numbers range from 188 to 229 except 189; they are accompanied by almost as many metastable excited states. The longest-lived isotope is 210At, which has a half-life of 8.1 hours, followed by the medically useful 211At, with a half-life of 7.214 hours. The longest-lived isomer is 202m1At with a half-life of just over 3 minutes. However, the longest-lived isotope existing in naturally occurring decay chains is 219At with a half-life of only 56 seconds.
Meglitinides help the pancreas produce insulin and are often called "short-acting secretagogues." They act on the same potassium channels as sulfonylureas, but at a different binding site. By closing the potassium channels of the pancreatic beta cells, they open the calcium channels, thereby enhancing insulin secretion. They are taken with or shortly before meals to boost the insulin response to each meal. If a meal is skipped, the medication is also skipped. Typical reductions in glycated hemoglobin (A1C) values are 0.5–1.0%.
=== Insects === Order Blattodea Blattella germanica, German cockroach (2018) Periplaneta americana, American cockroach (2018) Zootermopsis nevadensis, a dampwood termite (2014 Cryptotermes secundus, a drywood termite(2018) Macrotermes natalensis, a higher termite (2014 Order Coleoptera Dendroctonus ponderosae Hopkins, beetle (mountain pine beetle) (2013) Aquatica lateralis, Japanese aquatic firefly "Heike-botaru" (firefly) (2018) Photinus pyralis, Big Dipper firefly (2018) Protaetia brevitarsis, White-spotted flower chafer (2019) Tribolium castaneum Strain:GA-2, beetle (red flour beetle) (2008) Allomyrina dichotoma, Japanese rhinoceros beetle (2022) Pachyrhynchus sulphureomaculatus, Easter Egg Weevil (2021) Order Collembola Family Isotomidae Desoria tigrina, (2021) Family Sminthurididae Sminthurides aquaticus, (2021) Order Diptera Family Calliphoridae Aldrichina grahami, Forensic blowfly (2020) Family Chironomidae Dasypogon diadema, Hunting Robber fly (2019) Parochlus steinend, Antarctic winged midge (2017) Proctacanthus coquilletti, Assassin fly (2017) Family Culicidae (mosquitoes) Aedes aegypti Strain:LVPib12, mosquito (vector of dengue fever, etc.) (2007) Aedes albopictus (2015) Anopheles darlingi Anopheles gambiae Strain: PEST, mosquito (vector of malaria) (2002) Anopheles gambiae Strain: M, mosquito (vector of malaria) (2010) Anopheles gambiae Strain: S, mosquito (vector of malaria) (2010) Anopheles sinensis, mosquito (vector of vivax malaria, lymphatic filariasis and Setaria infections), (2014) Anopheles stephensii Anopheles arabiensis (2015) Anopheles quadriannulatus (2015) Anopheles merus (2015) Anopheles melas (2015) Anopheles christyi (2015) Anopheles epiroticus (2015) Anopheles maculatus (2015) Anopheles culicifacies (2015) Anopheles minimus (2015) Anopheles funestus (2015, 2019) Anopheles dirus (2015) Anopheles farauti (2015) Anopheles atroparvus (2015) Anopheles sinensis (2015) Anopheles albimanus (2015) Culex quinquefasciatus, mosquito (vector of West Nile virus, filariasis etc.) (2010) Family Drosophilidae (fruit flies) Drosophila albomicans, fruit fly (2012) Drosophila ananassae, fruit fly (2007) Drosophila biarmipes, fruit fly (2011) Drosophila bipectinata, fruit fly (2011) Drosophila erecta, fruit fly (2007) Drosophila elegans, fruit fly (2011) Drosophila eugracilis, fruit fly (2011) Drosophila ficusphila, fruit fly (2011) Drosophila grimshawi, fruit fly (2007) Drosophila kikkawai, fruit fly (2011) Drosophila melanogaster, fruit fly (model organism) (2000) Drosophila mojavensis, fruit fly (2007) Drosophila neotestacea, fruit fly (transcriptome 2014) Drosophila persimilis, fruit fly (2007) Drosophila pseudoobscura, fruit fly (2005) Drosophila rhopaloa, fruit fly (2011) Drosophila santomea, fruit fly () Drosophila sechellia, fruit fly (2007) Drosophila simulans, fruit fly (2007) Drosophila takahashi, fruit fly (2011) Drosophila virilis, fruit fly (2007) Drosophila willistoni, fruit fly (2007) Drosophila yakuba, fruit fly (2007) Family Phoridae Megaselia abdita, scuttle fly (transcriptome 2013) Family Psychodidae (drain flies) Clogmia albipunctata, moth midge (transcriptome 2013) Family Sarcophagidae (flesh flies) Sarcophaga Bullata, Flesh fly (2019) Family Syrphidae (hoverflies) Episyrphus balteatus, hoverfly (transcriptome 2011) Order Hemiptera Acyrthosiphon pisum, aphid (pea aphid) (2010) Ericerus pela, Chinese wax scale insect (2019) Laodelphax striatellus, small brown planthopper (2017) Lycorma delicatula, spotted lanternfly (2019) Rhodnius prolixus, kissing-bug (2015) Rhopalosiphum maidis, Corn leaf aphid (2019) Sitobion miscanthi, Indian grain aphid (2019) Triatoma rubrofasciata, assassin bug (2019) Order Hymenoptera Acromyrmex echinatior colony Ae372, ant (Panamanian leafcutter) (2011) Apis mellifera, bee (honey bee), (model for eusocial behavior) (2006) Atta cephalotes, ant (leaf-cutter ant) (2011) Camponotus floridanus, ant (2010) Cerapachys biroi, ant (clonal raider ant)(2014) Euglossa dilemma, Green orchid bee (2017) Harpegnathos saltator, ant (2010) Lasius niger, ant (black garden ant)(2017) Linepithema humile, ant (Argentine ant) (2011) Nasonia giraulti, wasp (parasitoid wasp) (2010) Nasonia longicornis, wasp (parasitoid wasp) (2010) Nasonia vitripennis, wasp (parasitoid wasp; model organism) (2010) Netelia fuscicornis, wasp (parasitoid wasp) (2024) Nomia Melanderi, Alkali bee (2019) Pogonomyrmex barbatus, ant (red harvester ant) (2011) Solenopsis invicta, ant (fire ant) (2011) Order Lepidoptera Abrostola tripartita Hufnagel, Spectacle (2021) Achalarus lyciades, Hoary Edge Skipper (2017) Ahamus jianchuanensis, Jianchuan ghost moth (2024) Antharaea yamamai, Japanese oak silk moth (2019) Arctia plantaginis, Wood tiger moth (2020) Bicyclus anynana, squinting bush brown (2017) Bombyx mori Strain:p50T, moth (domestic silk worm) (2004) Calycopis cecrops, Red-Banded Groundstreak (2016) Calycopis isobeon, Dusky-Blue Groundstreak (2016) Coenonympha arcania, Pearly Heath (2024) Cydia pomonella, codling moth (2019) Danaus plexippus, monarch butterfly) (2011) Erebia cassioides, Common Brassy Ringlet (2025) Heliconius melpomene, butterfly (2012) Keiferia lycopersicella, Tomato pinworm (2024) Melitaea cinxia, Glanville fritillary butterfly (2014) Megathymus ursus violae, bear giant skipper butterfly (2018) Morpho helenor, Common blue morpho (2023) Morpho achilles, Blue-banded morpho (2023) Morpho deidamia (2023) Papilio bianor, Chinese peacock butterfly (2019) Phthorimaea absoluta, Tomato leafminer (2024) Pieris rapae, small cabbage white butterfly (2016) Plodia interpunctella, Indianmeal moth (2022) Plutella xylostella, moth (diamondback moth) (2013) Scrobipalpa atriplicella, Goosefoot groundling moth (2024) Spodoptera frugiperda, Fall armyworm (2017) Thitarodes armoricanus, Himalaya ghost moth (2024) Thitarodes xiaojinensis, Xiaojin ghost moth (2024) Troides aeacus, Golden birdwing (2024) Eudocima phalonia, fruit-piercing moth (2017) Order Orthoptera Locusta migratoria, migratory locust (2014) Schistocerca gregaria, desert locust (2020) Gryllus bimaculatus, two-spotted cricket (2021) Order Phthiraptera Pediculus humanus, louse (sucking louse; parasite) (2010) Menopon gallinae, Poutlry shaft louse (2024) Psocoptera Liposcelis brunnea, booklouse (2022) Order Raphidioptera Venustoraphidia nigricollis, black-necked snakefly (2023) Order Trichoptera Eubasilissa regina, purple caddisfly (2022,) Stenopsyche tienmushanensisi, Caddisfly (2018) Order Mantodea Tenodera sinensis, chinese praying mantis (2023)
== Etymology and pronunciation == The word purpura () comes from Latin purpura, "purple", which came from ancient Greek πορφύρα. Purpura is a mass noun naming the condition or state, not the name of an individual spot (thus there is no *purpurum, *purpura or *purpura, *purpurae count declension).
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.